#CureLGMD2A

Publication shares development of new animal model of LGMD2A/R1

A paper published by Jason Berman, Children’s Hospital of Eastern Ontario Research Institute and University of Ottawa, along with colleagues from Dalhousie University, AGADA Biosciences, and Binghamton University – State University of New York, shares the development of a zebrafish

Join Coalition to Cure Calpain 3 in celebrating Rare Disease Day

Rare Disease Day takes place on the last day of February every year, with the goal of raising awareness about rare diseases and their impact on patients’ lives. Over 300 million people are living with one or more of over

Sarepta Community Update on LGMD programs

Sarepta Therapeutics recently published a Community Letter to share updates on their limb-girdle muscular dystrophy gene therapy programs. Click here to access the letter on Sarepta’s website.

New research grant aims to improve genetic diagnoses in individuals with CAPN3 mutations

Coalition to Cure Calpain 3 (C3) is pleased to announce a research grant has been awarded to Dr. Svetlana Gorokhova, working together with Dr. Marc Bartoli in the Translational Neuromyology Team, Marseille Medical Genetics Institute at Aix Marseille University. The

C3’s Countdown to the New Year

In 2022, C3 … Announced 5 new research projects Generated 4 novel mouse models for preclinical drug testing Co-organized an EL-PFDD meeting where 300+ individuals with LGMD tuned in to share their perspectives on what it is like to live

C3 partners with 16 LGMD organizations in letter to FDA

Coalition to Cure Calpain 3 is proud to be one of 17 organizations dedicated to LGMD to have collaborated on a statement submitted to the Food and Drug Administration in conjunction with the recent Patient-Focused Drug Development Meeting Patient Perspectives

Coalition to Cure Calpain 3

#CureLGMD2A

Publication shares development of new animal model of LGMD2A/R1

Join Coalition to Cure Calpain 3 in celebrating Rare Disease Day

Sarepta Community Update on LGMD programs

New research grant aims to improve genetic diagnoses in individuals with CAPN3 mutations

C3’s Countdown to the New Year

C3 partners with 16 LGMD organizations in letter to FDA

New LGMD2A/R1 Mice: Novel tools for drug development

Your voice made a difference!

The LGMD EL-PFDD is just one week away!

Casimir Recruiting LGMD2A/R1 Patients for At-Home Study